Pfizer has unveiled detailed survival data from a pivotal colorectal cancer trial, underscoring a potentially practice-changing advance for patients with a historically hard-to-treat mutation.

 

The company announced results from Cohort 3 of the Phase 3 BREAKWATER study, evaluating BRAFTOVI (encorafenib) in combination with cetuximab (ERBITUX) and FOLFIRI chemotherapy versus standard regimens with or without bevacizumab in previously untreated metastatic colorectal cancer (mCRC) carrying a BRAF V600E mutation.

 

The results confirm the study’s primary endpoint of objective response rate (ORR) and now deliver a striking signal in progression-free survival (PFS). Median PFS nearly doubled with the BRAFTOVI combination—15.2 months versus 8.3 months in the comparator arm. 

 

Patients receiving the targeted regimen saw a 56% reduction in risk of disease progression or death.

 

Updated overall survival data also point in the same direction. The regimen reduced the risk of death by 44%, with median overall survival not yet reached in the BRAFTOVI arm compared with 20.3 months in the control group. At 18 months, survival stood at 72% versus 54.5%.

 

“For people with BRAF V600E-mutant metastatic colorectal cancer – a disease that historically has had no targeted treatment options and poor outcomes – these results strengthen confidence in how we can treat this disease,” said Scott Kopetz, co-principal investigator of the BREAKWATER trial. 

 

“A nearly 60% reduction in risk of disease progression or death, combined with prolonged overall survival, reinforces the role of encorafenib in combination with cetuximab and FOLFIRI as a standard of care in the first-line setting for this patient population.”

 

"These compelling results add to a robust body of evidence demonstrating the efficacy of the BRAFTOVI combination treatment across two different established chemotherapy regimens in BRAF V600E-mutant metastatic colorectal cancer,” said Jeff Legos, Chief Oncology Officer, Pfizer. 

 

“These findings reaffirm the established role of the BRAFTOVI combination regimen as a cornerstone of first-line treatment for patients and families facing this challenging diagnosis.”

 

Safety findings were broadly consistent with known profiles of the individual drugs, with no new safety signals identified. 

 

The most common side effects included nausea, diarrhea, vomiting, anemia, fatigue, and decreased appetite. Grade 3 or higher adverse events occurred in 70.4% of patients receiving the BRAFTOVI combination versus 80.9% in the comparator arm, while treatment discontinuation rates were 15.5% and 10.3%, respectively.

 

Based on the full dataset from BREAKWATER, the combination therapy has already secured expanded FDA approval in February 2026 for first-line treatment of BRAF V600E-mutant mCRC, offering flexibility in chemotherapy backbone selection.

 

Colorectal cancer remains a major global health burden, ranking as the third most common cancer worldwide and the second leading cause of cancer-related death.

 

The BREAKWATER trial continues to position BRAFTOVI in combination therapy as a potential new backbone in first-line care for this high-risk patient population, as survival gains and progression delays begin to reshape expectations in BRAF V600E-mutant disease.